Abstract

Background: Pseudomonas aeruginosa (PSA) and Acinetobacter baumannii (ACB) are non-fermentative bacteria mostly associated with nosocomial infections in humans. Objective: This study aimed to determine the antimicrobial resistance profiles and virulence gene of PSA and ACB previously isolated from humans in selected health facilities in Yaoundé, Cameroon. Methods: A total of 77 and 27 presumptive PSA and ACB isolates, respectively, were collected from the Yaoundé teaching hospital. These isolates were previously isolated from various samples including pus, blood and broncho-alveolar lavage. The identities of the isolates were determined through polymerase chain reaction (PCR) amplification of PSA and ACB specific sequences. Antimicrobial susceptibility testing (AST) was performed using the Kirby–Bauer disc diffusion method. Phenotypical expression of AmpC β-lactamases (AmpC), extended spectrum β-lactamases (ESBLs) and metallo β-Lactamases (MBLs) were determined using the combined disc method. Bacterial genomes were screened for the presence of β-lactamases blaTEM and blaCTXM genes using specific PCR. The pathogenicity of PSA and ACB was assessed through amplification of the lasB, exoA, pslA and exoS as well as OmpA and csuE virulence genes, respectively. Results: Of the 77 presumptive PSA isolates, a large proportion (75 to 97.4%) were positively identified. All (100%) of the presumptive 27 ACB harbored the ACB-specific ITS gene fragment by PCR. Twenty five percent of the PSA isolates produced ESBLs phenotypically while more than 90% of these isolates were positive for the lasB, exoA, pslA and exoS genes. A large proportion (88%) of the ACB isolates harboured the OmpA and csuE genes. blaTEM and blaCTXM were detected in 17 and 4% of PSA, respectively, while a much higher proportion (70 and 29%) of the ACB isolates possessed these resistance determinants respectively. Conclusion: Our findings reveal the occurrence of both virulence and drug-resistant determinants in clinical PSA and ACB isolates from patients in health care settings in Yaoundé, Cameroon, thus suggesting their role in the pathological conditions in patients.

Highlights

  • Pseudomonas aeruginosa (PSA) and Acinetobacter baumannii (ACB) are important causative agents of nosocomial infections in humans with more severe complications in immunocompromised patients [1,2]

  • One hundred and four bacteria isolates comprising of 77 and 27 presumptive PSA and ACB from different clinical specimens, including pus, urine, sputum, bronco-alveolar lavage (BAL), sperm, high vaginal swab (HVS) and blood were collected from Yaoundé University Teaching Hospital (YUTH), Yaoundé Central Hospital (YCH) and Centre Pasteur du Cameroun (CPC) between January 2015 to March 2016

  • A total of 104 bacteria strains comprising 77 and 27 presumptive PSA and ACB isolates were collected from the health facilities in Cameroon

Read more

Summary

Introduction

Pseudomonas aeruginosa (PSA) and Acinetobacter baumannii (ACB) are important causative agents of nosocomial infections in humans with more severe complications in immunocompromised patients [1,2]. To the best of our knowledge, there are few reports on the carriage, expression of resistance genes, and virulence determinants among bacteria isolates [12,13,14,15] especially PSA and ACB of clinical origin in Cameroon [16]. This study was aimed at assessing the antimicrobial resistance and virulence determinants expressed by PSA and ACB isolates collected in some health settings in Yaoundé, Cameroon. Objective: This study aimed to determine the antimicrobial resistance profiles and virulence gene of PSA and ACB previously isolated from humans in selected health facilities in Yaoundé, Cameroon. Conclusion: Our findings reveal the occurrence of both virulence and drug-resistant determinants in clinical PSA and ACB isolates from patients in health care settings in Yaoundé, Cameroon, suggesting their role in the pathological conditions in patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call